Since malignant HSPCs, with their self‐renewal capacity, are a primary source of minimal residual disease after treatment and contribute significantly to the high risk of relapse in AML patients,[22, 23, 24] our investigation particularly focuses on the role of AP2M1 in HSPCs. Here, AP2M1 is linked to acute myeloid leukemia.